Document:

EX-10.3(g)

 EXHIBIT 10.3(g) 

AMENDMENT NO. 5 TO THE AMENDED AND RESTATED CREDIT AGREEMENT 

This Amendment No. 5 to the Amended and Restated Credit Agreement (this “Amendment No. 5”) dated as of May 6,
2013 (the “Amendment No. 5 Effective Date”) is entered into among Atlas Pipeline Partners, L.P., a Delaware limited partnership (the “Borrower”), the Subsidiaries of the Borrower identified as
“Guarantors” on the signature pages hereto (the “Guarantors”), the Lenders signatory hereto and Wells Fargo Bank, National Association, in its capacity as administrative agent for the Lenders (in such capacity, the
“Administrative Agent”) and amends the Amended and Restated Credit Agreement dated as of July 27, 2007 and amended and restated as of December 22, 2010 (as amended, supplemented or otherwise modified from time to time, the
“Credit Agreement”) entered into among the Borrower, the Guarantors named therein, the institutions from time to time party thereto as Lenders (the “Lenders”), the Administrative Agent and the other agents and
arrangers named therein. 
 Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the
Credit Agreement, as amended hereby. 
 W I T N E S S E T H: 

WHEREAS, pursuant to the Credit Agreement the Lenders have, subject to the terms and conditions set forth therein, made certain credit
available to and on behalf of the Borrower; 
 WHEREAS, Section 12.2 of the Credit Agreement provides that the Credit Agreement may be
amended, modified and waived from time to time; 
 WHEREAS, the Borrower has requested that the Administrative Agent and the Lenders agree
to amend the Credit Agreement as set forth herein; 
 WHEREAS, subject to certain conditions, the Lenders are willing to agree to the
amendments set forth in Section 1 hereof relating to the Credit Agreement; 
 NOW, THEREFORE, in consideration of the premises
and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the parties hereto hereby agree as follows: 

Section 1. Amendments to the Credit Agreement. 

(a) Section 1.1 of the Credit Agreement is hereby amended by amending and restating the definitions of “Consolidated
Subsidiary” and “TexStar JVs” in their entirety as follows: 
 “Consolidated
Subsidiary” means each Subsidiary of a Person (whether now existing or hereafter created or acquired) the financial statements of which shall be (or should have been) consolidated with the financial statements of such Person in accordance
with GAAP, provided, however, that the Consolidated Subsidiaries of Borrower shall (a) not include the Unrestricted Entities and (b) notwithstanding anything to the contrary contained in this Agreement, be deemed to include
(i) each Anadarko JV, (ii) the Centrahoma JV, (iii) T2 LaSalle 

 
Gathering Company LLC, a Delaware limited liability company, and (iv) T2 LaSalle Gas Utility LLC, a Texas limited liability company. 

“TexStar JVs” means T2 Eagle Ford Gathering Company LLC, a Delaware limited liability company, T2 LaSalle
Gathering Company LLC, a Delaware limited liability company, T2 EF Cogeneration Holdings LLC, a Delaware limited liability company, and each of their respective Subsidiaries. 

(b) Clause (a) of Section 9.3 of the Credit Agreement is hereby amended and restated in its entirety as follows: 

(a)(i) Investments existing on the Closing Date in Subsidiaries existing on the Closing Date, (ii) Investments existing on
the Closing Date (other than Investments in Subsidiaries existing on the Closing Date) and described on Schedule 9.3, (iii) Investments made after the Closing Date in the Borrower or any of the Guarantors, the Anadarko JVs, T2 LaSalle Gathering
Company LLC, a Delaware limited liability company, and T2 LaSalle Gas Utility LLC, a Texas limited liability company, or the Centrahoma JV, and (iv) Investments in T2 Eagle Ford Gathering Company LLC, a Delaware limited liability company, and
its Subsidiaries, and T2 EF Cogeneration Holdings LLC, a Delaware limited liability company, and its Subsidiaries that, in the case of this clause (iv), are deemed to be made as a result of the consummation of the Permitted TEAK Acquisition on the
closing date thereof; 
 (c) Section 9.13 is hereby and restated in its entirety to read in full as follows: 

SECTION 9.13 Disposal of Subsidiary Interests. Permit any Domestic Subsidiary (other than any Anadarko JV, the
Centrahoma JV and any TexStar JV) to be a non-Wholly-Owned Subsidiary except (a) as a result of or in connection with a dissolution, merger, amalgamation, consolidation or disposition permitted by Section 9.4 or 9.5 or (b) so long as
such Domestic Subsidiary continues to be a Guarantor. 
 Section 2. Conditions Precedent to the Effectiveness of this Amendment
No. 5. This Amendment No. 5 shall become effective as of the date hereof when, and only when, the Administrative Agent shall have received counterparts of this Amendment No. 5, duly executed by (a) the Borrower,
(b) the Guarantors, (c) the Administrative Agent and (d) the Required Lenders. 
 Section 3. Representations and
Warranties. On and as of the Amendment No. 5 Effective Date, after giving effect to this Amendment No. 5, the Borrower hereby represents and warrants to the Administrative Agent and each Lender as follows: 

(a) this Amendment No. 5 has been duly authorized, executed and delivered by the Borrower and constitutes the legal, valid and binding
obligation of the Borrower enforceable against the Borrower in accordance with its terms and the Credit Agreement, as amended by this Amendment No. 5, constitutes the legal, valid and binding obligation of the Borrower enforceable against the
Borrower in accordance with its terms. 
 (b) No Default or Event of Default under the Credit Agreement would exist immediately after giving
effect to this Amendment No. 5. 

  
 2 

 (c) No consent, approval, authorization or offer of, or filing, registration or qualification
with, any court or governmental authority or third party is required in connection with the execution, delivery or performance by such Person of this Amendment No. 5. 

(d) After giving effect to this Amendment No. 5, the representations and warranties set forth in Article VI of the Credit Agreement are
true and correct in all material respects as of the date hereof (except for those which expressly relate to an earlier date). 

Section 4. Reference to and Effect on the Loan Documents. 

(a) As of the Amendment No. 5 Effective Date, each reference in the Credit Agreement to “this Agreement,” “hereunder,”
“hereof,” “herein,” or words of like import, and each reference in the other Loan Documents to the Credit Agreement (including, without limitation, by means of words like “thereunder,” “thereof” and words of
like import), shall mean and be a reference to the Credit Agreement as amended hereby, and this Amendment No. 5 and the Credit Agreement shall be read together and construed as a single instrument. 

(b) As of the Amendment No. 5 Effective Date, Borrower hereby acknowledges that it has received and reviewed a copy of the Credit
Agreement and acknowledges and agrees to be bound by all covenants, agreements and acknowledgments in the Credit Agreement and any other Loan Document and to perform all obligations and duties required of it by the Credit Agreement. 

(c) Except as expressly amended hereby, all of the terms and provisions of the Credit Agreement and all other Loan Documents are and shall
remain in full force and effect and are hereby ratified and confirmed. 
 (d) The execution, delivery and effectiveness of this Amendment
No. 5 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the Lenders, the Borrower or the Administrative Agent under any of the Loan Documents, nor constitute a waiver or amendment of any other
provision of any of the Loan Documents or for any purpose except as expressly set forth herein. 
 (e) This Amendment No. 5 shall
constitute a Loan Document under the terms of the Credit Agreement. 
 Section 5. Acknowledgement of Guarantors. The
Guarantors acknowledge and consent to all terms and conditions of this Amendment No. 5 and agree that this Amendment No. 5 and all documents executed in connection herewith do not operate to reduce or discharge the Guarantors’
obligations under the Loan Documents. 
 Section 6. Confirmation of Security Documents. The Borrower hereby confirms and
ratifies all of its obligations under the Loan Documents to which it is a party. By its execution on the signature lines provided below, each of the Credit Parties hereby confirms and ratifies all of its obligations and the Liens granted by it under
the Security Documents to which it is a party, confirms that the Security Documents continue to grant valid Liens on the Collateral to the Collateral Agent for the benefit of the Secured Parties securing the Obligations, represents and warrants that
the representations and warranties set forth in such Security Documents are complete and correct on the date hereof as if made on and as of such date and confirms that all references in such Security Documents to the “Credit Agreement” (or
words of similar import) 

  
 3 

 
refer to the Credit Agreement as amended hereby without impairing any such obligations or Liens in any respect. 

Section 7. Execution in Counterparts. This Amendment No. 5 may be executed in any number of counterparts and by
different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate
counterparts and attached to a single counterpart so that all signature pages are attached to the same document. Delivery of an executed counterpart by telecopy or other electronic transmission (i.e., “pdf” or “tif” document)
shall be effective as delivery of a manually executed counterpart of this Amendment No. 5. 
 Section 8. Governing Law.
This Amendment No. 5 shall be governed by, and construed in accordance with, the laws of the State of New York without regard to principles of conflicts of law to the extent that the application of the laws of another jurisdiction
will be required thereby. 
 Section 9. Section Titles. The section titles contained in this Amendment No. 5 are
and shall be without substantive meaning or content of any kind whatsoever and are not a part of the agreement between the parties hereto, except when used to reference a section. Any reference to the number of a clause, sub clause or subsection of
any Loan Document immediately followed by a reference in parenthesis to the title of the section of such Loan Document containing such clause, sub clause or subsection is a reference to such clause, sub clause or subsection and not to the entire
section; provided, however, that, in case of direct conflict between the reference to the title and the reference to the number of such section, the reference to the title shall govern absent manifest error. If any reference to the
number of a section (but not to any clause, sub clause or subsection thereof) of any Loan Document is followed immediately by a reference in parenthesis to the title of a section of any Loan Document, the title reference shall govern in case of
direct conflict absent manifest error. 
 Section 10. Notices. All communications and notices hereunder shall be given as
provided in the Credit Agreement. 
 Section 11. Severability. The fact that any term or provision of this Amendment
No. 5 is held invalid, illegal or unenforceable as to any person in any situation in any jurisdiction shall not affect the validity, enforceability or legality of the remaining terms or provisions hereof or the validity, enforceability or
legality of such offending term or provision in any other situation or jurisdiction or as applied to any person. 
 Section 12.
Successors. The terms of this Amendment No. 5 shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns. 

Section 13. Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES TRIAL BY JURY IN ANY ACTION OR
PROCEEDING WITH RESPECT TO THIS AMENDMENT NO. 5 OR ANY OTHER LOAN DOCUMENT. 
 [Signature pages follow] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 5 to be executed under seal by their
duly authorized officers, all as of the day and year first written above. 
  

			
	BORROWER:
	
	ATLAS PIPELINE PARTNERS, L.P.
		
	By:	 	Atlas Pipeline Partners GP, LLC, its general partner
		
	By:	 	 /s/ ROBERT W. KARLOVICH, III

		 	Name: Robert W. Karlovich III
		 	Title: Chief Financial Officer
	
	GUARANTORS:
	
	ATLAS PIPELINE OPERATING PARTNERSHIP, L.P.
		
	By:	 	Atlas Pipeline Partners GP, LLC, its general partner
		
	By:	 	 /s/ ROBERT W. KARLOVICH, III

		 	Name: Robert W. Karlovich III
		 	Title: Chief Financial Officer
	
	ATLAS PIPELINE TENNESSEE, LLC
	APL LAUREL MOUNTAIN, LLC
	ATLAS PIPELINE MID-CONTINENT HOLDINGS LLC
		
	By:	 	Atlas Pipeline Operating Partnership, L.P., its sole member
		
	By:	 	Atlas Pipeline Partners GP, LLC, its general partner
		
	By:	 	 /s/ ROBERT W. KARLOVICH, III

		 	Name: Robert W. Karlovich III
		 	Title: Chief Financial Officer

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	ATLAS MIDKIFF, LLC
	ATLAS CHANEY DELL, LLC
	SLIDER WESTOK GATHERING, LLC
	NOARK ENERGY SERVICES, L.L.C.
	ATLAS PIPELINE MID-CONTINENT LLC
	APL BARNETT, LLC
	ATLAS PIPELINE NGL HOLDINGS, LLC
	ATLAS PIPELINE NGL HOLDINGS II, LLC
	APL ARKOMA HOLDINGS, LLC
	APL GAS TREATING, LLC
		
	By:	 	Atlas Pipeline Mid-Continent Holdings, LLC, its sole member
		
	By:	 	Atlas Pipeline Operating Partnership, L.P., its sole member
		
	By:	 	Atlas Pipeline Partners GP, LLC, its general partner
		
	By:	 	 /s/ ROBERT W. KARLOVICH, III

		 	Name: Robert W. Karlovich III
		 	Title: Chief Financial Officer
	
	VELMA INTRASTATE GAS TRANSMISSION COMPANY, LLC
	VELMA GAS PROCESSING COMPANY, LLC
		
	By:	 	Atlas Pipeline Mid-Continent LLC, its sole member
		
	By:	 	Atlas Pipeline Mid-Continent Holdings, LLC, its sole member
		
	By:	 	Atlas Pipeline Operating Partnership, L.P., its sole member
		
	By:	 	Atlas Pipeline Partners GP, LLC, its general partner
		
	By:	 	 /s/ ROBERT W. KARLOVICH, III

		 	Name: Robert W. Karlovich III
		 	Title: Chief Financial Officer

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	PECOS PIPELINE LLC
	TESUQUE PIPELINE, LLC
		
	By:	 	APL Barnett, LLC, its sole member
		
	By:	 	Atlas Pipeline Mid-Continent Holdings, LLC, its sole member
		
	By:	 	Atlas Pipeline Operating Partnership, L.P., its sole member
		
	By:	 	Atlas Pipeline Partners GP, LLC, its general partner
		
	By:	 	 /s/ ROBERT W. KARLOVICH, III

		 	Name: Robert W. Karlovich III
		 	Title: Chief Financial Officer
	
	APL ARKOMA, INC.
		
	By:	 	 /s/ ROBERT W. KARLOVICH, III

		 	Name: Robert W. Karlovich III
		 	Title: Chief Financial Officer
	
	APL ARKOMA MIDSTREAM, LLC
		
	By:	 	APL Arkoma Holdings, LLC, its sole member
		
	By:	 	Atlas Pipeline Mid-Continent Holdings, LLC, its sole member
		
	By:	 	Atlas Pipeline Operating Partnership, L.P., its sole member
		
	By:	 	Atlas Pipeline Partners GP, LLC, its general partner
		
	By:	 	 /s/ ROBERT W. KARLOVICH, III

		 	Name: Robert W. Karlovich III
		 	Title: Chief Financial Officer

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent and a Lender
		
	By:	 	 /s/ JASON M. HICKS

		 	Name: Jason M. Hicks
		 	Title: Managing Director

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	BANK OF AMERICA, N.A., as a Lender
		
	By:	 	 /s/ ADAM H. PEY

		 	Name: Adam H. Pey
		 	Title: Director

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	CITIBANK, N.A., as a Lender
		
	By:	 	 /s/ MASON MCGURRIN

		 	Name: Mason McGurrin
		 	Title: Vice-President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	DEUTSCHE BANK TRUST COMPANY AMERICAS, as a Lender
		
	By:	 	 /s/ MICHAEL GETZ

		 	Name: Michael Getz
		 	Title: Vice President
		
	By:	 	 /s/ DUSAN LAZAROV

		 	Name: Dusan Lazarov
		 	Title: Director

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	COMPASS BANK, as a Lender
		
	By:	 	 /s/ ANN VAN WAGENER

		 	Name: Ann Van Wagener
		 	Title: Senior Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	SUNTRUST BANK, as a Lender
		
	By:	 	 /s/ DAVID M. FELTY

		 	Name: David M. Felty
		 	Title: Director

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	ABN AMRO CAPITAL USA LLC, as a Lender
		
	By:	 	  

		 	Name:                                     
                   
		 	Title:

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	AMEGY BANK, N.A., as a Lender
		
	By:	 	 /s/ WILLIAM B. ROBINSON

		 	Name: William B. Robinson
		 	Title: Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

			
	SUMITOMO MITSUI BANKING CORPORATION, as a Lender
		
	By:	 	 /s/ JAMES D. WEINSTEIN

		 	Name: James D. Weinstein
		 	Title: Managing Director

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	BRANCH BANKING AND TRUST
COMPANY, as a Lender
		
	By:	 	 /s/ JAMES GIORDANO

		 	Name: James Giordano
		 	Title: Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	JPMORGAN CHASE BANK, N.A., as a Lender
		
	By:	 	  

		 	Name:
		 	Title:

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

 
			
	CAPITAL ONE, NATIONAL ASSOCIATION,
as a Lender
		
	By:	 	 /s/ ROBERT S. JAMES

		 	Name: Robert S. James
		 	Title: Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

			
	COMERICA BANK, as a Lender
		
	By:	 	 /s/ JOHN S. LESIKAR

		 	Name: John S. Lesikar
		 	Title: Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

			
	CADENCE BANK, N.A., as a Lender
		
	By:	 	 /s/ WILLIAM W. BROWN

		 	Name: William W. Brown
		 	Title: Senior Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

			
	ONEWEST BANK, FSB, as a Lender
		
	By:	 	 /s/ SEAN MURPHY

		 	Name: Sean Murphy
		 	Title: Executive Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

			
	REGIONS BANK, as a Lender
		
	By:	 	 /s/ DAVID VALENTINE

		 	Name: David Valentine
		 	Title: Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

			
	SOVEREIGN BANK, N.A., as a Lender
		
	By:	 	 /s/ AIDAN LANIGAN

		 	Name: Aidan Lanigan
		 	Title: SVP
		
	By:	 	 /s/ DAVID O’DRISCOLL

		 	Name: David O’Driscoll
		 	Title: SVP

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

			
	GOLDMAN SACHS BANK USA, as a Lender
		
	By:	 	 /s/ MICHELLE LATZONI

		 	Name: Michelle Latzoni
		 	Title: Authorized Signatory

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P. 

			
	THE F&M BANK AND TRUST COMPANY,
as a Lender
		
	By:	 	 /s/ HENRY SMITH

		 	Name: Henry Smith
		 	Title: Vice President

  
 SIGNATURE
PAGE 
 AMENDMENT NO. 5- ATLAS PIPELINE PARTNERS,
L.P.EX-10.1

 Exhibit 10.1 

THIRD AMENDMENT TO 

PARTICIPATION AGREEMENT 
 This THIRD
AMENDMENT TO THE PARTICIPATION AGREEMENT (the “Third Amendment”) is executed on June 17, 2014 (“Effective Date”) by and between Cleveland BioLabs, Inc., a Delaware corporation (“CBL”), and Limited Liability Company
Bioprocess Capital Partners, a company duly organized and existing under the laws of the Russian Federation (“BCP”), a management company of the venture fund Bioprocess Capital Ventures. 

RECITALS 
 A. CBL and BCP have entered
into that certain Participation Agreement dated as of December 30, 2009 (the “Participation Agreement”), as amended by the First Amendment to Participation Agreement dated as of April 13, 2010 (the “First Amendment”),
and further amended by the Second Amendment to Participation Agreement dated as of November 22, 2013 (the “Second Amendment”), with regard to the management of Limited Liability Company Incuron, a company duly organized and existing
under the laws of the Russian Federation (the “Company”), its formation and capital funding; and 
 B. The Parties intend to ensure the due
execution of certain actions arising out of the occurrence of an event described in the Participation Agreement, in particular in the Section relating to redistribution of percentage shares of participation interests upon completion of
participants’ capital contributions. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants hereinafter set forth, CBL
and BCP effected the following amendments to the Participation Agreement: 
 1. Definitions. All capitalized terms not defined in this Third Amendment shall
have the meanings set forth for them in the Participation Agreement. 
 2. Additional Definitions. The following definitions are hereby added by this Third
Amendment to the Participation Agreement: 
 ““GCP” means the then-current standards, practices and procedures promulgated or endorsed by
the US Food and Drug Administration (“FDA”) as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements imposed by the FDA, as may be
updated from time to time.” 
 3. Section 2.2(b)(ii) of the Participation Agreement is hereby amended and restated in its entirety as set
forth below: 
 “(ii) A second tranche in the total amount of 179,927 thousand Rubles shall be made in two payments by August 1, 2014 (the
“Second Milestone Payment”). 
 4. Section 2.2(d) of the Participation Agreement is hereby amended and restated in its entirety as set
forth below: 
 “After the contributions have been made, the nominal value of the Participation Interests of BCP will be increased by the respective
amount of all of its contributions into the Company’s charter capital.” 

 5. Section 2.2(h) of the Participation Agreement is hereby amended and restated in its entirety as set forth
below: 
 “For the purposes of this Third Amendment “Second Milestone” shall mean: (A) completion of Phase Ib and receipt of
permission to conduct Phase II clinical studies in Russia, (B) submission of an Investigational New Drug application to the FDA and (C) confirmation of participation in a Phase I clinical study by at least one clinical center in the United
States. 
 The Participants hereby agree that as of the date of this Agreement, the Second Milestone has been achieved.” 

6. A new Section 2.5 is hereby added to the Participation Agreement as follows: 

2.5 Participation in Future Financing. 
 (a)
CBL shall have the right to participate in any farther equity financing of the Company pro rata in accordance with applicable Russian legislation. 
 7.
A new Section 6.4 is hereby added to the Participation Agreement as follows: 
 “6.4 Entire clinical development of CBL0137 conducted by or on
behalf of Incuron shall be performed in accordance with all applicable laws, including all applicable GCP.” 
 8. Section 3 of the First
Amendment is hereby terminated in its entirety, effective as of the Effective Date hereof. 
 9. The following provisions are hereby inserted at the end of
Section 2 of the First Amendment: 
 a. Upon BCP effecting in full the Second Milestone Payment, the Parties shall recalculate the percentage share
of BCP’s Participation Interest in the Company based on the formula set forth in Section 2 of the First Amendment to the Participation Agreement. 

b. In case the value of D calculated in accordance with the formula set forth in Section 2 of the First Amendment to the Participation Agreement
exceeds 49.99% of the Company’s charter capital, BCP shall have the right to demand that CBL sell to it a part of CBL’s participation interest in the Company at the nominal price in the amount of the difference between the calculated value
of D and 49.99% and CBL shall have the obligation to comply with such demand within ten (10) business days upon its receipt. 
 c. The demand
for mandatory sale as provided for in Section 9b. of this Third Amendment shall be made in writing and shall include the calculation of participation interest to be sold, the demand for sale and demand for execution of the Principal Agreement
(as this term is defined in the First Amendment (“BCP Notice”). 

  
 2. 

 d. The Parties shall within ten (10) business days upon receipt by CBL of BCP Notice: 

i. execute the Principal Agreement and perform all the actions required for the execution of the sale-purchase transaction in respect of the participation
interest in the Company in accordance with Section 9b. of this Third Amendment; and 
 ii. appoint the new Board of Directors of the Company in
accordance with provisions of this Third Amendment. 
 e. The Parties shall within thirty (30) business days upon receipt by CBL of BCP Notice
adopt a new Charter of the Company in the form mutually agreed upon by CBL and BCP. 
 10. The following provisions of the Participation Agreement shall
be deemed amended from the date of receipt by CBL of BCP Notice: 
  

	•	 	Section 3.l(b) of the Participation Agreement shall be amended and restated in its entirety as set forth below: 

“(b) The Board of Directors shall consist of five (5) directors, comprised as follows: 

(i) two (2) directors nominated by BCP (the “BCP Directors”); 

(ii) two (2) directors nominated by CBL (the “CBL Directors”); and 

(iii) one (1) director nominated by the majority of the CBL Directors and the BCP Directors voting together; provided, that, in the event of a tie,
the parties hereby agree that Mr. Mogutov, as a BCP Director, shall have the deciding vote.” 
  

	•	 	Section 3.1(i) of the Participation Agreement shall be amended and restated in its entirety as set forth below: 

“The presence of three (3) directors shall be required for the taking of any action by the Board. In exercising its powers under
Section 3.2(a), the Board shall act by the vote of a majority of the directors present.” 
  

	•	 	Section 3.2(a) of the Participation Agreement shall be amended as set forth below: 

  

	•	 	Section 3.2(a)(i) shall be amended and restated in its entirety as set forth below: 

 (i) appoint or
remove members of the Management Committee and set their compensation packages and approve the appointment or removal of other senior management of the Company and their compensation packages; 

 

	•	 	Section 3.2(a)(iii) shall be deleted and replaced with “Deleted.” 

  

	•	 	The following clauses shall be inserted after Section 3.2(a)(vi): 

 (vii) approval of a detailed budget
(monthly) based on an approved Business Plan; 

  
 3. 

 (viii) establishing any bonus compensation plans for the members of the Management Committee; 

(ix) the acquisition, disposition or encumbrance of any assets of the Company not provided for in the Business Plan, provided that the transaction does not
involve any transfer of the Company’s intellectual property rights and the aggregate value of the assets, whether in one transaction or a series of related transactions, does not exceed twenty five percent (25%) of the total asset value of
the Company as determined from the Company’s most recent Accounting Statements prior to the date of the applicable transaction; and 
 (x)
decisions on other matters in accordance with procedures set forth by the Company’s charter and in the event of a conflict between this Agreement and the Company’s charter, the Company’s charter shall take precedence. 

 

	•	 	Section 3.2(b) of the Participation Agreement shall be amended and restated in its entirety as set forth below: 

“Notwithstanding the foregoing, the consent of eighty percent (80%) of the members of the Board shall be required to approve (collectively,
(i) through (vi) below are hereinafter referred to as the “Supermajority Decisions”): 
 (i) the Business Plan and any amendments
thereto; 
 (ii) any deviation over 15% from an approved Business Plan as determined pursuant to quarterly reviews; 

(iii) strategic decisions affecting a substantial part of the Business of the Company not provided for in the Business Plan, including any transaction
outside the ordinary course of business which is expected to result in an increase in operating costs greater than fifteen million Russian Rubles (RU 15,000,000), whether in one transaction or in a series of related transactions, but not to exceed
twenty five percent (25%) of the total asset value of the Company as determined from the Company’s most recent Accounting Statements prior to the date of the applicable transaction; 

(iv) any decision relating to capital investments by, or the financing of the Company not provided for in the Business Plan, including the provision or
incurrence of indebtedness or the provision of any guarantee, in each case with a value in excess of RU 15,000,000 (or its equivalent in any other currency) whether in one transaction or in a series of related transactions, but not to exceed twenty
five percent (25%) of the total asset value of the Company as determined from the Company’s most recent Accounting Statements prior to the date of the applicable transaction; 

(v) create or invest in one or more subsidiary entities; acquire, finance, dispose of or otherwise deal with securities of any kind of nature; and 

  
 4. 

 (vi) any action involving the transfer of the intellectual property rights of the Company, but not to exceed
twenty five percent (25%) of the total asset value of the Company as determined from the Company’s most recent Accounting Statements prior to the date of the applicable transaction, including, without limitation: 

A. disposal of patents and granting of licenses to use the Company’s inventions in accordance with existing patents; 

B. sale (transfer) of intellectual property rights which qualify for know-how protection; granting of licenses to use know-how rights; and 

C. execution of any agreement with a third party (a “Client”) for the performance of research, research/development and development works, which
is subject to a transfer of intellectual property rights originating from the performance of such agreements for the Client or subject to the possession of such works jointly with the Client in any form. 

 

	•	 	A new Section 3.2(c) of the Participation Agreement shall be added as set forth below: 

“Notwithstanding the foregoing, the consent of eighty percent (80%) of the members of the Board shall be required to approve contracts (or
related contracts) or investments in the aggregate, with cost equal to or greater than twenty-five percent (25%) of total asset value of the Company as determined from the Company’s most recent Accounting Statements prior to the date of
the applicable transaction.” 
  

	•	 	Section 3.4(d) of the Participation Agreement shall be deleted in its entirety and replaced with “Deleted”. 

  

	•	 	Section 4.1 of the Participation Agreement shall be amended and restated in its entirety as set forth below: 

“Except as provided in Section 3.6, no Participant shall make any Transfer of Participation Interests except for Transfers of Participation
Interests made pursuant to a Bona Fide Offer and pursuant to the Principal Agreement in accordance with the provisions of Section 3 of this Second Amendment, in the latter case Sections 4.4 and 4.5 of the Participation Agreement shall not
apply.” 
 11. The Parties shall exercise their voting rights under the Charter or applicable legislation at any general meeting and take all
actions necessary to implement the arrangements referred to by the Participation Agreement and this Third Amendment. 
 12. Remedy of the breach shall not
absolve the breaching Participant from its responsibility that arose during or as a result of its failure to perform its obligation under this Third Amendment. 

13. All terms and provisions of the Participation Agreement other than amendments set forth in this Third Amendment shall remain in full force and are not
subject to change. 
 14. This Third Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Delivery of an executed counterpart of this Amendment electronically or by 

  
 5. 

 
facsimile shall be effective as delivery of an original executed counterpart of this Amendment, provided that it shall be followed-up by an original of such counterpart signature within five
(5) business days thereafter. 
 15. This Third Amendment has been made in Russian and English language. In the event of a conflict or inconsistency
between the English and Russian versions of the agreement, the Russian version shall prevail. 
 In witness whereof, CBL and BCP have executed this Third
Amendment to the Participation Agreement as of the date first above written. 
  

			
	Cleveland BioLabs, Inc.
		
	By:	 	 /s/ Yakov Kogan

		
	Title:	 	CEO
	
	Managing Company Bioprocess Capital Partners LLC
		
	By:	 	 /s/ Vladamir Tezov

		
	Title:	 	 General Director

  
 6.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]